A new analysis raises serious questions about the increasingly common use of second-generation antidepressant drugs to treat anxiety disorders. It concludes that studies supporting the value of these medications for that purpose have been distorted by publication bias, outcome reporting bias and 'spin,' and suggests that their effectiveness has been exaggerated.